Unlabelled: Ceftolozane-tazobactam (C/T) recommended dosing in patients undergoing renal replacement therapies (RRT) is lacking evidence. The objective of this study was to evaluate the clinical outcomes of C/T dosing in patients on RRT.
Materials And Methods: A retrospective descriptive study conducted at our institution between May 1, 2017, and March 15, 2022.
Introduction: The suggested dose of ceftazidime-avibactam (CEF/AVI) in patient with multidrug resistant organisms and utilizing renal replacement therapies (RRTs) is not validated in clinical studies. The objective of this study was to evaluate the microbiologic cure of bacteremia and pneumonia using the recommended CEF/AVI dosing in patients utilizing RRT.
Methods: A retrospective observational study conducted at our institution between September 15, 2018 and March 15, 2022.